Dr. Jukes P. Namm, MD

Dr. Namm practices at Loma Linda University Medical Center in Loma Linda, California, part of Seventh-day Adventist Church.

Dr. Namm's NPI, 1336355957, was assigned on May 14, 2007. Dr. Namm graduated from Loma Linda University School Of Medicine in 2005. Dr. Namm's California license number on file is A97112.

Dr. Namm's primary practice is Loma Linda University Medical Center, at 11234 Anderson St, Loma Linda, CA 92354 in San Bernardino County. The practice phone is (909) 558-4000.

Dr. Namm's primary practice is Loma Linda University Medical Center in Loma Linda, California, part of Seventh-day Adventist Church. Dr. Namm is also affiliated with Loma Linda University Medical Center - Murrieta. The medical group on file is Loma Linda University Faculty Medical Group (LLUFMG). Dmand AI also links Dr. Namm to 1 more group practice or clinic, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Namm practices, 3 sites in all. Vendor and product names are available with a free account.

Surgery is Dr. Namm's primary specialty in the NPI Registry, under taxonomy code 208600000X. Dr. Namm is board certified in complex general surgical oncology by the American Board of Surgery. Dmand AI has Dr. Namm's licenses on file in 3 states: California, Illinois and Michigan.

Dmand AI lists abdominal adhesion surgery, colon removal and mastectomy among the conditions Dr. Namm treats.

CMS data shows 116 Medicare services from Dr. Namm across 4 procedure codes in 2024, for 118 Medicare patients. Medicare paid $10,683 for them.

CMS counts 118 Medicare patients who saw Dr. Namm in 2024. The largest group is 65 to 74, with 63 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 39% are also on Medicaid. Their average risk score is 1.81, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Namm's median patient age at 67, with 74% women.

In 2024, Dr. Namm wrote 69 Medicare Part D claims for 36 patients. 93% of them were for generic drugs. CMS names the drug for 11 of them, across 1 drug with 11 or more claims each, at $97 in total drug cost. In 2022, CMS named 12 claims across 1 drug.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 89 out of 100 for Dr. Namm for performance year 2024, reported as part of a group. Dr. Namm accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS counts 11 procedures of mastectomy by Dr. Namm, more than 64% of the clinicians it reports for that procedure.

Melanoma (skin cancer) excision: 1 to 10 procedures (CMS shows small counts as a range)

Dmand AI links 39 papers to Dr. Namm, published from 2008 to 2025. 2020 was the busiest year, with 3. The most frequent topics are Breast Neoplasms, Sentinel Lymph Node Biopsy and Skin Neoplasms. Dr. Namm has published most often in Am Surg. Dr. Namm's most frequent co-authors are Sharon S. Lum, MD, Naveenraj Livingstone Solomon, MD and Mark Evan Reeves, MD.

CMS Open Payments shows 16 general payments to Dr. Namm from 8 drug and device companies from 2016 to 2024. Food and beverage make up the largest share, 100% of the total. Terumo Medical Corporation paid the most, $150.

Dmand AI lists 2 awards for Dr. Namm, most recently Young Fellow Award in 2017. Dr. Namm serves on Clinical Ethics Committee.

Dr. Namm graduated from Loma Linda University School Of Medicine in 2005. Dr. Namm is a member of ACS, ASCO, Association of Program Directors in Surgery and SSO.

Dr. Namm is in network with 15 carriers, including Aetna, Elevance and Blue Cross Blue Shield of Michigan. Medicare plans come from the most carriers, 9. Check the plan with the practice before a visit.